Decoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV

September 29, 2026 — 08:15 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Tuesday, Decoy Therapeutics (DCOY) said preclinical pharmacokinetic data support once-weekly intranasal dosing of its lead program DCOY-CoV, designed to protect against endemic human coronaviruses.

DCOY-CoV is an investigational antiviral designed to target conserved mechanisms across coronaviruses, including SARS-CoV-2 and common cold coronaviruses.

In preclinical studies, a single intranasal dose maintained drug levels above designed therapeutic concentrations in nasal and lung tissues for up to seven days, supporting its potential for extended respiratory protection.

The company said the program is being developed for high-risk populations, including immunocompromised individuals and patients with chronic respiratory conditions.

Decoy expects DCOY-CoV to enter clinical trials in 2027.

Decoy's stock closed Monday's trading at $2.31, down 25.24%. In pre-market trading the stock is at $2.30, down 0.37%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Decoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV

Tags

Latest Articles